Close

Anti-LAG3 DNA-encoded mAb (DMAb), pVAX1 (DMAb-4014-FY)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This product is the plasmid containing an encoded anti-LAG3 DMAb sequence. The plasmid can drive transcription and in vivo translation of the desired antibody.

  Add to Cart

Specifications

  • Target
  • LAG3
  • Vector Name
  • pVAX1
  • Vector Description
  • pVAX1 was originally designed for the development of DNA vaccines. Its eukaryotic DNA sequences limited to the expression of desired sequence so that minimize the possibility of chromosomal integration. This vector has been widely used for the construction of DMAb plasmid.
  • Vector Promoter
  • CMV
  • Vector Tag or Fusion
  • Untagged
  • Delivery Method
  • Transfection
  • Cloning Method
  • Restriction Enzyme ⁄ MCS
  • Constitutive or Inducible System
  • Constitutive
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term.
  • Background
  • DNA-encoded mAb (DMAb) technology is a novel approach for a direct in vivo production of desired biologically active immunoglobulins according to the plasmid DNA delivery into tissue where the delivered plasmid containing an encoded antibody sequence. Compared with the traditional mAb, DMAb can be functionally equivalent with additional advantages such as expression profiles, glycosylation, as well as no reliance on in vivo tissue culture and costly or time-consuming production systems. The DMAb technology may provide a novel, simple, less frequent, cost-effective approach for therapeutics.

Target

  • Entrez Gene ID
  • 3902
Sub CAT. DMAb Clone DMAb Host Target Species DMAb Isotype DMAb Immunogen  
DMAb-0799-YJ 12K124 Rat Mouse IgG2b Recognizes mouse LAG-3. Does not react with recombinant human LAG-3.
DMAb-0800-YJ 7E155 Rat Mouse IgG1 Murine CD223 Ig fusion protein.
DMAb-0801-YJ C9B7W Rat Mouse IgG1 Murine CD223 Ig fusion protein. Cells from immunised Lewis rats were fused with cells of the Sp/20 myeloma cell line.
DMAb-0734-YJ 11E3 Mouse IgG1 Recombinant human LAG-3.
DMAb-0735-YJ 17B4 Mouse Human IgG1 Synthetic peptide corresponding to 30 aa in the N-terminus of human LAG-3.
DMAb-0736-YJ 3C39 Mouse Human IgG2 Human recombinant LAG-3.
DMAb-0737-YJ 5C3 Mouse Human IgG2b
DMAb-0738-YJ 6D511 Mouse IgG1 Recognizes the first N-terminal D1 domain of human LAG-3. Species Crossreactivity: monkey.
DMAb-0739-YJ 6D65 Mouse Human IgG1 Synthetic peptide corresponding to 30AA, GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3).
DMAb-0740-YJ 8F6 Mouse Human IgG2b Human recombinant protein fragment corresponding to amino acids 66-332 of human LAG3 (NP_002277) produced in E.coli.
DMAb-0741-YJ 8G6 Mouse Human IgG2b Human recombinant protein fragment corresponding to amino acids 66-332 of human LAG3(NP_002277) produced in E. coli.ImmunogenType: Recombinant protein.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-LAG3 DNA-encoded mAb (DMAb), pVAX1 (DMAb-4014-FY). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.